Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group.

This article examines the occurrence of eosinophilic granulomatosis with polyangiitis (EGPA) in patients with severe asthma who are being treated with anti-T2 monoclonal antibodies (mAbs). The study involved 30 EGPA patients from different countries who developed the disease while on anti-T2 therapy for severe asthma. The patients were receiving various mAbs, such as omalizumab, benralizumab, mepolizumab, dupilumab, and reslizumab. The article provides demographic, clinical, and treatment-related information about the study population. The findings suggest that EGPA can still develop in these patients despite the use of anti-T2 mAbs, and monitoring blood eosinophil count may be important in predicting disease progression. However, more research is needed to fully understand the relationship between EGPA and anti-T2 mAbs. [Extracted from the article]